Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 315

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Selective estrogen receptor modulation

Open access
Jordan, V.Craig·2004·Cancer Cell
DOI 10.1016/s1535-6108(04)00059-5
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(04)00059-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 55

  1. ATAC Trialists' Group, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 · DOI · Paper page
  2. Brzozowski, 1997, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, 389, 753, 10.1038/39645 · DOI · Paper page
  3. Chisamore, 2001, Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha, Clin. Cancer Res., 7, 3156
  4. Chlebowski, 2003, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women, JAMA, 289, 3243, 10.1001/jama.289.24.3243 · DOI · Paper page
  5. Cummings, 1999, The effect of raloxifene on risk of breast cancer in postmenopausal women, Multiple Outcomes of Raloxifene Evaluation. JAMA, 281, 2189
  6. EBCTCG, 1998, Tamoxifen for early breast cancer, Lancet, 354, 1451
  7. Enmark, 1999, Oestrogen receptors—an overview, J. Intern. Med., 246, 133, 10.1046/j.1365-2796.1999.00545.x · DOI · Paper page
  8. Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene, JAMA, 282, 637, 10.1001/jama.282.7.637 · DOI · Paper page
  9. Fisher, 1994, Endometrial cancer in tamoxifen-treated breast cancer patients, J. Natl. Cancer Inst., 86, 527, 10.1093/jnci/86.7.527 · DOI · Paper page
  10. Fisher, 1998, Tamoxifen for prevention of breast cancer, J. Natl. Cancer Inst., 90, 1371, 10.1093/jnci/90.18.1371 · DOI · Paper page
  11. Font de Mora, 2000, AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor, Mol. Cell. Biol., 20, 5041, 10.1128/MCB.20.14.5041-5047.2000 · DOI · Paper page
  12. Fornander, 1989, Adjuvant tamoxifen in early breast cancer, Lancet, 1, 117, 10.1016/S0140-6736(89)91141-0 · DOI · Paper page
  13. Goss, 2003, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N. Engl. J. Med., 349, 1, 10.1056/NEJMoa032312 · DOI · Paper page
  14. Gottardis, 1987, Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model, Cancer Res., 47, 4020
  15. Gottardis, 1988, Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse, Cancer Res., 48, 812
  16. Hall, 2002, Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements, Mol. Endocrinol., 16, 469, 10.1210/mend.16.3.0814 · doi:10.1210/mend.16.3.0814 · Paper page
  17. Jensen, 2003, The estrogen receptor, Clin. Cancer Res., 9, 1980
  18. Jordan, 1984, Biochemical pharmacology of antiestrogen action, Pharmacol. Rev., 36, 245
  19. Jordan, 2001, Selective estrogen receptor modulation, Cancer Res., 61, 5683
  20. Jordan, 2003, Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions, J. Med. Chem., 46, 883, 10.1021/jm020449y · DOI · Paper page
  21. Jordan, 2003, Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents, J. Med. Chem., 46, 1081, 10.1021/jm020450x · DOI · Paper page
  22. Jordan, 2003, Tamoxifen, Nat. Rev. Drug Discov., 2, 205, 10.1038/nrd1031 · DOI · Paper page
  23. Jordan, 1980, Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model, Eur. J. Cancer, 16, 239, 10.1016/0014-2964(80)90156-5 · DOI · Paper page
  24. Jordan, 1987, Effects of anti-estrogens on bone in castrated and intact female rats, Breast Cancer Res. Treat., 10, 31, 10.1007/BF01806132 · DOI · Paper page
  25. Khan, 2003, Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17 beta-estradiol in breast cancer cells, Endocrinology, 144, 2325, 10.1210/en.2002-0149 · DOI
  26. Lauritsen, 2002, A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells, Oncogene, 21, 7147, 10.1038/sj.onc.1205943 · DOI
  27. Lerner, 1990, The development of antiestrogens for the treatment of breast cancer, Eighth Cain Memorial Award Lecture. Cancer Res., 50, 4177
  28. Levin, 2003, Bidirectional signaling between the estrogen receptor and the epidermal grwoth factor receptor, Mol. Endocrinol., 17, 309, 10.1210/me.2002-0368 · DOI · Paper page
  29. Lewis, 2004, Targeting oestrogen to kill the cancer but not the patient, Br. J. Cancer, 90, 822, 10.1038/sj.bjc.6601611 · DOI · Paper page
  30. Liu, 2002, Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells, J. Biol. Chem., 277, 9189, 10.1074/jbc.M108335200 · doi:10.1074/jbc.m108335200
  31. Liu, 2003, Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo, J. Natl. Cancer Inst., 95, 1586, 10.1093/jnci/djg080 · DOI
  32. Lonard, 2004, Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins, Mol. Cell. Biol., 24, 14, 10.1128/MCB.24.1.14-24.2004 · DOI
  33. Lonning, 2001, High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy, Breast Cancer Res. Treat., 67, 111, 10.1023/A:1010619225209 · DOI · Paper page
  34. Love, 1992, Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer, N. Engl. J. Med., 326, 852, 10.1056/NEJM199203263261302 · DOI · Paper page
  35. MacGregor Schafer, 2000, Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351, Cancer Res., 60, 5097
  36. McDonnell, 2002, Connections and regulation of the human estrogen receptor, Science, 296, 1642, 10.1126/science.1071884 · DOI · Paper page
  37. McKenna, 1999, Nuclear receptor coregulators, Endocr. Rev., 20, 321
  38. Meyers, 2001, Estrogen receptor beta potency-selective ligands, J. Med. Chem., 44, 4230, 10.1021/jm010254a · DOI · Paper page
  39. Mosca, 2001, Design and methods of the Raloxifene Use for The Heart (RUTH) study, Am. J. Cardiol., 88, 392, 10.1016/S0002-9149(01)01685-X · DOI · Paper page
  40. MWSC, 2003, Million Women Study Collaborators). Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14065-2 · DOI · Paper page
  41. Newman, 2000, Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer, Oncogene, 19, 490, 10.1038/sj.onc.1203416 · DOI
  42. Osborne, 2003, Role of the estrogen receptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer, J. Natl. Cancer Inst., 95, 353, 10.1093/jnci/95.5.353 · DOI · Paper page
  43. Osipo, 2003, Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer, J. Natl. Cancer Inst., 95, 1597, 10.1093/jnci/djg079 · DOI
  44. Pike, 2001, Structural insights into the mode of action of a pure antiestrogen, Structure, 9, 145, 10.1016/S0969-2126(01)00568-8 · DOI · Paper page
  45. Razandi, 1999, Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript, Endocrinology, 13, 307
  46. Robertson, 2003, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women, Cancer, 98, 229, 10.1002/cncr.11468 · DOI · Paper page
  47. Shang, 2002, Molecular determinants for the tissue specificity of SERMs, Science, 295, 2465, 10.1126/science.1068537 · DOI · Paper page
  48. Shiau, 1998, The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen, Cell, 95, 927, 10.1016/S0092-8674(00)81717-1 · DOI · Paper page
  49. Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women, JAMA, 289, 2651, 10.1001/jama.289.20.2651 · DOI · Paper page
  50. Song, 2001, Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol, J. Natl. Cancer Inst., 93, 1714, 10.1093/jnci/93.22.1714 · DOI · Paper page
  51. Stauffer, 2000, Pyrazole ligands, J. Med. Chem., 43, 4934, 10.1021/jm000170m · DOI · Paper page
  52. Turner, 1987, Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats, J. Bone Miner. Res., 2, 449, 10.1002/jbmr.5650020513 · DOI · Paper page
  53. Webb, 1995, Tamoxifen activation of the estrogen receptor/AP-1 pathway, Mol. Endocrinol., 9, 443
  54. Wijayaratne, 2001, The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators, J. Biol. Chem., 276, 35684, 10.1074/jbc.M101097200 · DOI · Paper page
  55. Yao, 2000, Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice, Clin. Cancer Res., 6, 2028

Cited by

See all 315

Metadata

Authors
Jordan, V. C.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2004-03
Volume
5
Issue
3
Pages
207-213
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/s1535-6108(04)00059-5
OpenAlex
W1966538470
Cited by
315
References
1
FWCI
14.82
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective estrogen receptor modulation. https://app.cochat.ai/papers/10.1016/s1535-6108(04)00059-5
The paper
Jordan, V. C. (2004). Selective estrogen receptor modulation. Cancer Cell. https://doi.org/10.1016/s1535-6108(04)00059-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.